Prana announces dosing of first patient in PBT2 Phase II trial for Alzheimer’s disease

Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that the first patient has been dosed in the 12-month open label extension study with Alzheimer’s Disease patients participating in Prana’s Phase 2 IMAGINE trial.

Patients who have completed the full 12-month term of the IMAGINE trial are eligible for participation in the open-label extension study. All participants in the extension study will receive a 250mg once daily oral dose of PBT2 for an additional 12 months.

The IMAGINE trial is a 12-month double-blind Phase II clinical trial of PBT2 in Alzheimer’s patients. The Extension study does not alter the completion and reporting on this trial with results expected in March 2014.

Prana’s Chairman and CEO, Geoffrey Kempler, said: “Dosing commenced earlier than anticipated because of patient interest in participating in this Extension study and support from the physicians involved.”

Professor Rudy Tanzi, the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Prana’s Chief Scientific Advisor, added: “PBT2 is the most promising therapy currently in clinical trials for the treatment of Alzheimer's disease".

Source: http://www.pranabio.com/